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Objective
To determine the cost-effectiveness of the current ‘gold standard’ operation of transurethral resection of the prostate
(TURP) compared to the new laser technique of thulium laser transurethral vaporesection of the prostate (ThuVARP) in
men with benign prostatic obstruction (BPO) within the UK National Health Service (NHS).
Patients and Methods
The trial was conducted across seven UK centres (four university teaching hospitals and three district general
hospitals). A total of 410 men aged ≥18 years presenting with either bothersome lower urinary tract symptoms
(LUTS) or urinary retention secondary to BPO, and suitable for surgery, were randomised (whilst under anaesthetic)
1:1 to receive the TURP or ThuVARP procedure. Resource use in relation to the operation, initial inpatient stay,
and subsequent use of NHS services was collected for 12 months from randomisation (equivalent to primary
effectiveness outcome) using hospital records and patient questionnaires. Resources were valued using UK reference
costs. Quality adjusted life years (QALYs) were calculated from the EuroQoL five Dimensions five Levels (EQ-5D-5L)
questionnaire completed at baseline, 3- and 12-months. Total adjusted mean costs, QALYs and incremental Net
Monetary Benefit statistics were calculated: cost-effectiveness acceptability curves and sensitivity analyses addressed
uncertainty.
Results
The total adjusted mean secondary care cost over the 12 months in the TURP arm (£4244) was £9 (95% CI –£376, £359)
lower than the ThuVARP arm (£4253). The ThuVARP operation took on average 21 min longer than TURP. The adjusted
mean difference of QALYs (0.01 favouring TURP, 95% CI 0.01, 0.04) was similar between the arms. There is a 76%
probability that TURP is the cost-effective option compared with ThuVARP at the £20 000 per QALY willingness to pay
threshold used by National Institute for Health and Care Excellence (NICE).
Conclusion
One of the anticipated benefits of the laser surgery, reduced length of hospital stay with an associated reduction in cost, did
not materialise within the study. The longer duration of the ThuVARP procedure is important to consider, both from a
patient perspective in terms of increased time under anaesthetic, and from a service delivery perspective. TURP remains a
highly cost-effective treatment for men with BPO.
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Introduction
In the UK, 25 000 men are operated on annually to relieve the
symptoms caused by benign prostatic obstruction (BPO), and
TURP is the most common procedure undertaken [1,2]. The
small but significant mortality and morbidity risks associated
with the TURP procedure including haemorrhage, transurethral
resection (TUR) syndrome and UTIs [3] have led to the
development of new technologies for treating men with BPO.
The UK National Institute for Health and Care Excellence
(NICE) currently recommends the following interventions for
men with BPO: TURP; holmium laser enucleation of the
prostate (HoLEP) (in centres specialising in the technique)
[4]; and GreenLight XPS laser [5] for lower risk patients.
TURP remains the standard with which new techniques
should be compared.
The thulium laser technique vaporises and resects the
prostate, using a surgical technique similar to TURP,
facilitating a shorter learning curve and potentially making it
quickly generalisable. In China, a randomised controlled trial
(RCT) [6] and a non-randomised prospective controlled trial
[7] compared TURP and thulium laser transurethral
vaporesection of the prostate (ThuVARP). This led to the
European Association of Urology (EAU) guidelines on laser
technologies [8] stating that ThuVARP shows equivalent
efficacy to TURP. However, no trial within a recent
systematic review of the two techniques reported costs,
although the associated meta-analysis did find a shorter
length of stay in favour of ThuVARP [9].
In the UK, the UNBLOCS multicentre, pragmatic,
randomised, controlled, parallel-group trial showed that both
ThuVARP and TURP were effective treatments for men with
BPO, with TURP having some minor benefits compared with
ThuVARP at 12 months [10].
The present article presents the within-trial individual patient
data cost-effectiveness analysis of the UNBLOCS trial over a
12 month period from a secondary care UK NHS perspective




Men in seven UK secondary care centres were invited to
participate in the trial if they were aged ≥18 years and
presented with either urinary retention or bothersome LUTS,
secondary to BPO, and were suitable for TURP surgery. The
design of the trial has been published previously [11]. In
brief, men meeting the study’s inclusion criteria and who
gave fully informed consent were randomised, once they were
anaesthetised in the operating theatre, to receive either TURP
or ThuVARP in a 1:1 ratio between June 2014 to December
2016 and were followed up for 12 months post-
randomisation/surgery. Participants were blinded to which
procedure they received during their involvement in the trial.
ThuVARP was selected for comparison rather than thulium
enucleation as it easier to learn, so facilitating the opportunity
for widespread adoption into clinical practice. All surgeons
were familiar with laser use for procedures such as stone
surgery, and some had used HoLEP/Greenlight XPS. All
surgeons were trained to conduct the ThuVARP procedure
before starting the trial, as published elsewhere [11]. As
patients were randomised in theatre, sites made the decision
on whether to list patients as daycase or inpatient procedures
irrespective of their surgical arm. Ethical Approval was given
by the National Research Ethics Service (NRES) Committee
South Central - Hampshire B Ethics Committee (13/SC/
0644).
Resource use Measurement and Valuation
Resource use data in relation to the initial surgery and any
subsequent treatment for the man’s BPO were collected for
12 months post-randomisation from three main sources; Trial
Case Report Forms (CRFs); Hospital Patient-linked
information costing systems (PLICS), and patient-completed
questionnaires.
Study research nurses within the treating hospitals recorded
resource use information relating to the operation and
postoperative stay onto CRFs capturing items such as surgery
time, use of disposable theatre equipment, complications,
unscheduled returns to the operating theatre, and any time
spent on different postoperative wards.
PLICS is an electronic NHS cost reporting tool which has
information in the form of International Statistical
Classification of Diseases (ICD)10, Office of Population
Censuses and Surveys Classification of Interventions and
Procedures version 4 (OPCS-4) and Health Resource Group
(HRG) codes, on specific patient events related to their
secondary care healthcare use. Data on subsequent inpatient
stays, daycases, admissions, and outpatient visits and
procedures were obtained from PLICS for six out of the seven
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centres. For one centre where this was not possible, all
inpatient stays and outpatient visits were manually extracted
from the hospital systems. We defined the secondary care
NHS perspective as resource use data obtained from the CRFs
and hospital systems.
A questionnaire collecting resource use data directly from
participants at 3- and 12-months follow-up was either posted
to or given to the men in clinic for completion at home. The
questionnaires were used to collect information on
community-based healthcare use (e.g. GP visits, district nurse
visits), non-treating hospital secondary care healthcare use,
and medications resulting from their treatment. The NHS
perspective is defined as resource use information obtained
from all sources. All study data were managed using REDCap
[12] hosted at the University of Bristol.
All resource use and the unit costs (2016/17 UK prices) used
to value the respective resources are given in Table 1 [13–18]
Information from the Hospital Trust finance department
from one participating hospital was used in costing the
operation and the initial hospital stay. Information from
equipment manufacturers was used to cost all theatre
equipment, which differed between the two procedures. UK
reference costs were used to value subsequent inpatient stays,
outpatient visits, and procedures and community-based
healthcare [13,14].
Outcome Measurement
The economic outcome for the analysis is given in quality
adjusted life years (QALYs) as recommended by NICE [19].
At baseline participants completed the five level EQ-5D
(EQ-5D-5L) questionnaire in clinic, while at 3- and 12-
months it was either posted to or given to the men at clinic
for completion at home. At 6 weeks of follow-up the EQ-5D-
5L was administered by post. The EQ-5D-5L values were
transformed into utility scores [20]. QALYs for each patient
were calculated from the utility scores using the area under
the curve approach, taking into account any deaths that
occurred during the study [21].
Missing Data
Simple imputation was used for missing data items occurring
during the operation (see Table 1 for details). In relation to
the missing items from the resource use questionnaires, if the
questionnaire had been returned and an item was missing it
was assumed that no resource had been used.
Multiple imputations by chained equations were then used.
The model included: baseline, 6-weeks, 3- and 12-months
utility variables, trial arm, baseline diagnosis of LUTS or
urinary retention, baseline comorbidities, age, and centre. In
all, 54 individual imputations were conducted and combined
using Rubin’s rules [22] in relation to both perspectives using
a randomisation seed to enable reproducible imputations.
Analysis
The economic analyses were conducted under an intention-
to-treat approach analysing the groups as they were
randomised. STATA 15.1 [23] was used for all analyses.
Discounting did not occur in this study as discounting in
economic evaluations only occurs if the follow-up for a study
is >1 year.
The cost of each item of resource used during the 12 months
of follow-up was calculated by multiplying the resource use
(e.g. number of laser fibres) by its unit cost and summed by
resource use category (e.g. laser consumables) for each
participant.
Adjusted mean costs and QALYs by trial arm and the
differences in adjusted mean costs and QALYs (and their
associated 95% CIs) between trial arms were estimated using
the seemingly unrelated regressions (SUR) method, which
accounts for the correlation between costs and QALYs [24].
Costs and QALYs were adjusted for the randomisation
stratification variables, centre and bothersome LUTS or
urinary retention. Additionally, QALYs were adjusted for
baseline utility.
The secondary care costs and NHS costs were compared with
QALYs in turn. Within each perspective, if neither treatment
was more expensive and less effective than the other,
incremental cost-effectiveness ratios (ICERs) were created
using SUR. The incremental Net Monetary Benefit (NMB)
statistic that summarises the differences in costs and QALYs
of TURP compared with ThuVARP, at the standard NICE
willingness to pay threshold of £20 000 per QALY [19], was
calculated using the SUR outputs. A positive statistic would
indicate that TURP is the cost-effective option.
To explore sample uncertainty within the cost-effectiveness
estimates, cost-effectiveness acceptability curves (CEACs)
were calculated from individual NMB values at each
willingness-to-pay per QALY threshold (£0 to £100 000). The
CEAC shows the probability that TURP is the cost-effective
option compared with ThuVARP at different willingness to
pay per QALY thresholds.
The following one-way sensitivity analyses were conducted to
test the robustness of different parameter estimates and
assumptions made in relation to items of resource use and
costs in relation to the secondary care analysis.
• A complete case analysis (i.e. including only participants
with complete data, i.e. no simple or multiple imputation
was used).
• The exclusion of prostate cancer-related hospital resource
use.
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• The application of the average times of theatre by arm and
centre from the last 25% of cases to all other cases. This
was conducted in order to examine whether there is a
learning curve effect in the time taken to conduct the
THuVARP operations, as all surgeons were trained in the
technique for the purposes of the trial.
• The exclusion of post-recovery ward costs for those
patients who were randomised to ThuVARP in centres
where daycase TURP procedures were not conducted, to
examine the cost implication of being able to conduct
the ThuVARP procedure as a daycase. In the trial all
patients in these centres had to be listed as inpatient
procedures.
• The exclusion of the capital equipment costs (e.g. the
laser and the TURP generator) from both operations to
reflect the fact that often manufacturers do not charge for
capital equipment provided enough consumables are
purchased; adjusting the number of people that would
have had the operation in a year to reflect a high use and
a low use of the equipment; and the addition of TURP
capital costs to those randomised to ThuVARP to account
for TURP equipment needing to be available because of
conversions to TURP during the trial in part due to
equipment issues.
• The application of an alternative recovery time cost (£2.58/
min) based on a recent surgical microcosting study [25] to
acknowledge that the cost per hour of recovery based on a
medi room (a room to which patients are admitted to,
prepared for and recovered from surgery and discharged
from, if an overnight stay is not required) may not reflect
recovery costs in other institutions.
Results
A total of 410 participants were randomised in the
UNBLOCS study. Resource use and cost data from the CRFs
and hospital systems (the secondary care NHS perspective)
were available for 385 men (95% of the 407 randomised men
who did not withdraw their data). Missing data within the
resource use questionnaires meant that the completeness of
the resource use and cost data reduced to 47% once
information from all data sources was used (the NHS
Table 1 Resources collected and their valuation (2016/17 prices excluding value-added tax [VAT]).
Resource Unit cost, £ Source of cost
Theatre time 15.70/mina Finance Department of a treating hospital
Recovery ward 12.71/minb Finance Department of a treating hospital
Laser capital and reusable equipmentd 93.61c Manufacturer
Laser consumablese Varies Manufacturer
TURP capital and reusable equipmentf 15.81c Manufacturer
TURP consumablesg Varies Manufacturer
Blood transfusion 498.26 NHS reference cost [13]
Ward 360/day Finance Departments of a treating hospital
HDU/ITU 1300/day Finance Departments of a treating hospital
Subsequent inpatient stays Variesh NHS reference costs [13]
Curtis and Burns (2017) [14]
Day cases Varies NHS reference costs [13]
Outpatient visits Variesi NHS reference costs( [13]
Outpatient procedures Variesj NHS reference costs [13]
Accident and emergency attendances (no admission) 147.80 NHS reference costs [13]
GP surgery visit 29k,l Curtis and Burns (2017) [14]
GP home visit 89.44k,l,m Curtis and Burns (2013) [15]
GP telephone call 14.60 Curtis and Burns (2017) [14]
GP nurse visit 5.53 l,n Curtis and Burns (2017) [14]
District nurse visit 38.68m Curtis (2015) [16]
Community continence nurse visit 83 NHS reference costs [13]
NHS 111 call 12.26 Pope et al. (2017) [17]
Community-based urology service visit 103 NHS reference costs [13]
Medicationo Varies The Drug Tarriff [18]
aThe theatre unit cost of £15.70/min is an adjusted cost to avoid double counting of equipment. This adjusted cost is allocated to initial theatre time. The unadjusted unit cost of
£17/min is employed for return to theatre cases (n = 2) and for cases where neither ThuVARP, TURP or conversion procedures were carried out (n = 7). If the start of resection
time was missing (n = 35), The anaesthetic start time was used. bIf the time leaving recovery ward or discharge time (for day cases) was missing (n = 52) then a three-hour
duration was used based on information given by one of the hospitals. cCosts are derived from the number of TURP operations performed annually in a single operating theatre (n
= 260), the cost from the manufacturer and the lifespan of the equipment (in order to calculate an ‘annual equivalent cost’) and the annual maintenance costs dThe laser capital
and reusable equipment cost includes the laser machine, working element, cystoscope, bridge, telescope, light lead, sheath, outer sheath, visual obturator and laser goggles. eLaser
consumables costs comprises of laser fibres, biopsy forceps and evacuator kits. If the type of laser fibre used was missing (n = 5) a reusable fibre was assumed, if number of reusable
laser fibres were missing (n = 14) one was assumed. fTURP capital and reusable equipment costs the TURP generator, working element, telescope, light lead, inner sheath, outer
rotating sheath, bipolar lead and visual obturator. gTURP consumables cost consist of the cost of loop electrodes, roller electrodes, biopsy forceps and evacuator kits. hThe elective
inpatient cost related to the relevant HRG was used. iA consultant led unit cost relating to the relevant service code (i.e. speciality) was used. jThe unit cost relating to the Service
code and relevant HRG was used. If the HRG was missing the overall unit cost for the relevant service code was used. kExcluding direct care staff costs lExcluding qualification costs
mHospital and Community Health Services (HCHS) index was used to inflate costs to 2016–17 prices nBased on the assumption of a 9.22-min consultation oIf dosage was missing
then the usual dose was used.
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perspective). The EQ-5D-5L data were complete for 89% of
men at baseline; 82% at 6 weeks, 78% at 3 months and 81%
at 12 months, although intermittent missingness meant that
complete QALY data was only obtained for 212 participants
(52%). The amount of missing data meant that the cost,
QALY and SUR analyses were conducted using the multiple
imputed (MI) dataset comprising all 407 randomised men
(TURP n=204 and ThuVARP n=203).
The operation took on average 21 min longer in the
ThuVARP arm than in the TURP arm (Table 2), whereas
those in the TURP arm spent 14 min longer in recovery. Few
patients overall spent time in High Dependency Units
(HDUs)/Intensive Therapy Units (ITUs), but more time was
spent there by patients in the TURP arm. Patients in the
TURP arm also had a slightly higher number of subsequent
inpatient stays and outpatient visits, and slightly less follow-
up daycase admissions than those in the ThuVARP arm, as
well as slightly more community-based health service contacts
and medications (Table 2).
In the analysis from the secondary care NHS perspective,
the total adjusted mean costs in the TURP arm were
slightly lower (£4244) than the ThuVARP arm (£4252), a
cost difference of just £9 (95% CI –£376, £359) (Table 3).
From the wider NHS perspective, which included primary
care costs, this cost difference reduces slightly to £4 (95%
CI –£375, £366) resulting from the slightly higher
community care use in the TURP arm. Men in the TURP
arm had slightly more adjusted mean QALYs (0.84) than
those in ThuVARP arm (0.83) (Table 3), the difference of
0.01 (95% CI –0.01, 0.04) is equivalent to an extra 4 days of
the best imaginable health in favour of TURP during
12 months.
The incremental NMB at a £20 000 per QALY threshold of
TURP compared with ThuVARP in relation to the NHS
secondary care perspective was £236.24 (95% CI £419.48,
£891.96) and in relation to the wider NHS perspective was
£231.57 (95% CI £429.32, £892.46).
Figures 1 and 2 depict the CEACs for the two different
perspectives and indicate that at the willingness to pay
threshold of £20 000 per QALY, the probability that TURP
was the cost-effective treatment compared with ThuVARP
was 76% for the NHS secondary care perspective and 75% for
the wider NHS perspective.
The sensitivity analyses (Table 4) showed that with one
exception the initial results were robust in that the
incremental NMB at a £20 000 per QALY threshold of TURP
compared with ThuVARP was positive. In the case of
excluding the post-recovery ward costs to examine costing
ThuVARP as daycase surgery, TURP was no longer both
cheaper and more effective than ThuVARP and had an
incremental NMB of £98.95 (95% CI £745, £547) at the
threshold of £20 000 per QALY. Using an alternative cost for
recovery not only increased the cost difference in favour of
TURP, but also led to a decrease in overall costs for both
arms £2719 (TURP) and £2834 (ThuVARP).
Table 2 Mean (SD) resource usea by category and randomised allocation.b
Resource use category (unit of resource use measurement) TURP ThuVARP
N Resource use, mean (SD) N Resource use, mean (SD)
Theatre time, min 196 61.50 (28.57) 191 82.48 (33.57)
Recovery ward, min 196 157.58 (170.75) 191 143.97 (138.43)
Laser reusable equipment,uses, n 204 0 203 0.93 (0.26)
Laser consumables, n 204 0 202 2.23 (0.88)
TURP reusable equipment, uses, n 204 0.98 (0.14) 203 0.24 (0.43)
TURP consumables, n 204 2.54 (0.72) 203 0.42 (0.83)
Blood transfusion, units, n 204 0.005 (0.70) 203 0.00
Ward, days 204 1.67 (1.43) 203 1.55 (1.21)
HDU/ITU, days 203 0.02 (0.28) 203 0.005 (0.07)
Subsequent inpatient stays, n 204 0.08 (0.32) 203 0.06 (0.26)
Subsequent day cases, n 204 0.24 (0.48) 203 0.28 (0.66)
Outpatient visits, n 204 1.29 (1.72) 203 1.18 (1.73)
Outpatient procedures, n 204 0.25 (0.61) 203 0.26 (0.56)
Inpatient stays at other NHS hospitals, n 151 0.01 (0.11) 144 0.00 (0.00)
Outpatient visits at other NHS hospitals, n 151 0.71 (1.48) 144 1.12 (1.70)
Accident and Emergency Department visits, n 145 0.08 (0.41) 139 0.09 (0.53)
Face-to-face GP contacts, n 136 0.79 (1.85) 128 0.57 (1.66)
Telephone calls with GP, n 119 0.33 (1.47) 116 0.16 (0.57)
District nurse visit, n 122 0.16 (0.53) 117 0.15 (0.98)
Community-based health service contacts, n 117 0.27 (1.26) 110 0.12 (0.60)
Medications, n 138 0.05 (0.33) 123 0.03 (0.25)
aThe mean resource use is presented rather than absolute numbers or percentages to allow clinicians/decision makers to apply their own costs to the resources used, which improves
transparency and aids decision making. bSimple imputation methods as outlined in Table 1 were used to create the dataset from which the resource use in this table were estimated.
© 2020 The Authors
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Discussion
The total adjusted mean NHS secondary care costs for the
12 months of the trial within the TURP arm were £9 less
than those in the ThuVARP arm, which reduced to £4 when
community-based healthcare costs were included. The greater
length of time needed to conduct the ThuVARP procedure
meant the ThuVARP arm remained slightly more expensive,
despite longer recovery time and slightly greater postoperative
resource use for patients in the TURP arm. Although these
costs were very similar, the slightly lower costs and a slightly
higher QALY score within the TURP arm meant the
probability that TURP is the cost-effective option is at least
76% at all thresholds at and above £20 000 per QALY. The
sensitivity analyses with one exception reinforced the
certainty around this result.
The expected lower costs in the ThuVARP arm resulting
from an anticipated reduction in hospital stay and potential
to be done as a daycase did not materialise. To some extent
the ability to conduct ThuVARP as a daycase was affected by
an artefact of the trial, as patients in each site had to be listed
as daycase or inpatient stays prior to admission because
randomisation was conducted at the point of surgery. At two
sites both procedures could be listed as a daycase, due to an
unrelated move by their respective trusts to conduct TURP
procedures as day cases; however, at the remaining five sites
all procedures were listed as inpatient stays. In the UK more
TURPs are now being conducted as day cases, which could
be a reason for an equal mean length of stay (2 days) for
TURP and laser procedures within England [26]. Any effect
on costs of being able to use a daycase procedure for
ThuVARP in five of the centres where daycase TURPs were
not being conducted was examined through exclusion of
post-recovery ward costs for patients who were randomised
to ThuVARP in these five centres. The analysis showed there
were lower costs in the ThuVARP arm in this scenario
(£3909 vs £4245). This is based on the scenario in these five
centres that ThuVARP will always be a daycase procedure. In
the two centres in which daycase TURPs were conducted,
47% of ThuVARP procedures were conducted as daycases
and there was a mean ward stay of 1.77 days for ThuVARP
patients who stayed overnight. There would therefore be a
much smaller difference in cost than implied by the
sensitivity analysis, as ward costs would be incurred for some
ThuVARP patients.
The sensitivity analysis in which the average times of theatre
by arm and centre from the last 25% of cases was applied to
all other cases confirmed that no learning curve effect was
found for ThuVARP. This may have been the result of all
surgeons having to complete a training programme before
being involved in the trial, which included an independent
assessment prior to conducting laser procedures within the
trial [27
Table 3 Cost consequence results.a
Variable N
TURP:ThuVARP
Adj. TURP Adj. ThuVARP Adj. difference in
Mean (95% CI) Mean (95% CI) Mean (95% CI)
NHS secondary care perspective costs, £ 204:203 4244.12 (3985.12, 4503.11) 4252.92 (3992.29, 4513.54) 8.80 (–376.24, 358.64)
NHS perspective costs, £ 204:203 4305.23 (4043.75, 4566.71) 4309.45 (4046.08, 4572.82) 4.22 (375.04, 366.60)
QALY 204:203 0.84 (0.82, 0.86) 0.83 (0.81, 0.85) 0.01 (0.01, 0.04)
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]. The TURP procedure took on average 21 min less than the
ThuVARP procedure; this cumulative effect on an operating
list could lead to an extra TURP procedure being put onto
each half-day list, helping to reduce time on waiting lists.
During the trial there were 18 laser equipment failures: nine
prior to the start of surgery and nine during surgery, which
meant a TURP procedure was commenced or these
procedures were converted to TURPs. A further 27
conversions to TURP also occurred mainly because of very
large prostate size (nine patients), bleeding (four), poor
visibility (four), and to collect remaining fragments of
prostate (four). Although the sensitivity analysis that added
the TURP capital costs to those randomised to ThuVARP
and received ThuVARP only led to a mean increase in cost of
just over £9, the laser appears to be required as an additional
rather than a replacement piece of capital equipment.
The present study is the first individual patient economic
evaluation within a randomised trial investigating the cost-
effectiveness of TURP with ThuVARP for men with BPO.
However, the findings in the present study are supported by
Table 4 Sensitivity analysis.
N Adjusted mean Adjusted Incremental Incremental ICER Incremental
costsb, £ QALYsb Costs, £ QALYs £/QALY NMB (£) at
Mean (95% CI) Mean (95% CI) (95% CI) (95% CI) £20 000/QALY (95% CI)
Complete case analysisa
TURP 77 3528.74 0.87
(3182.88, 3874.61) (0.84, 0.90) ThuVARP
ThuVARP 75 4085.53 0.84 556.79 0.03 dominated by 1185.53
(3735.04, 4436.02) (0.81, 0.87) (1051.63, 61.94) (0.009, 0.072) TURP (259.87, 2111.18)
The exclusion of prostate cancer-related hospital resource use
TURP 204 4219.71 0.84
(3963.99, 4475.43) (0.82, 0.86)
ThuVARP 203 4192.06 0.83 27.65 0.01 2270.32 215.93
(3934.95, 4449.16) (0.81, 0.85) (335.35, 390.65) (0.01, 0.04) (451.29, 883.15)
Application of the average times of theatre from the last 25% of cases by arm in each centre, all other casesc
TURP 185 4179.60 0.84
(3915.71, 4443.49) (0.82, 0.86) ThuVARP
ThuVARP 183 4252.56 0.83 72.96 0.01 dominated by 1382.08
(3986.43, 4518.70) (0.81, 0.85) (447.42, 301.50) (0.02, 0.04) TURP (725.31, 2038.85)
Exclusion of post-recovery ward costs for those patients who had a ThuVARP procedure in centres where daycase TURP procedures were not conducted
TURP 204 4244.57 0.84
(3988.76, 4500.39) (0.82, 0.86)
ThuVARP 203 3909.32 0.83 335.25 0.01 £28375.12 98.95
(3654.55, 4164.09) (0.81, 0.85) (25.54, 696.05) (0.01, 0.04) (744.81, 546.90)
Excluding the cost of the laser machine and TURP generator
TURP 204 4238.27 0.84
(3979.01, 4497.53) (0.82, 0.86)
ThuVARP 203 4186.80 0.83 51.47 0.01 £4534.61 175.55
(3927.69, 4445.91) (0.81, 0.85) (315.26, 418.20) (0.01, 0.04) (481.00, 832.10)
Capital and reusable equipment costs based on 100 uses
TURP 204 4278.79 0.84
(4018.28, 4539.30) (0.82, 0.86) ThuVARP
ThuVARP 203 4400.13 0.83 121.34 0.01 dominated by 343.87
(4137.97, 4662.29) (0.81, 0.85) (489.91, 247.22) (0.01, 0.04) TURP (298.96, 986.70)
Capital and reusable equipment costs based on 500 uses
TURP 204 4239.92 0.84
(3981.04, 4498.79) (0.82, 0.86)
ThuVARP 203 4209.23 0.83 30.69 0.01 2671.38 199.04
(3949.04, 4469.42) (0.81, 0.85) (337.12, 398.49) (0.01, 0.04) (451.38, 849.47)
The need for TURP equipment to be available because of failures in ThuVARP equipment
TURP 204 4243.68 0.84
(3983.94, 4503.43) (0.82, 0.86) ThuVARP
ThuVARP 203 4261.36 0.83 17.68 0.01 dominated by 268.38
(4003.38, 4519.33) (0.81, 0.85) (384.08, 348.73) (0.01, 0.04) TURP (373.83, 910.59)
The use of an alternative recovery time cost of £2.58/min
TURP 204 2719.29 0.84
(2524.44, 2914.15) (0.82, 0.86) ThuVARP
ThuVARP 203 2833.54 0.83 114.25 0.01 dominated by 338.67
(2637.78, 3029.3) (0.81, 0.85) (390.42, 161.92) (0.01, 0.04) TURP (275.89, 953.22)
aIncluding only participants for whom we had complete cost and QALY information. bAdjusted for the minimisation variables of the randomisation process: study centre and
baseline diagnosis. Additionally, QALYs were adjusted for baseline score. cOne centre was excluded from this analysis as the last 25% of the operations in one of the arms had
missing data for time of operation.
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previous research [28] comparing a non-contact side-firing
neodymium:yttrium-aluminum-garnet (YAG) probe to TURP,
which found TURP to be the most cost-effective treatment
option in terms of symptomatic improvements. Other studies,
comparing TURP to other laser procedures have indicated
lower costs for the laser procedures: in the United States,
photoselective vaporisation of the prostate (PVP) vs TURP
($4266 vs $5097) [29]; in Australia, PVP vs TURP (AU$3368
vs AU$4,292) [30]; and in New Zealand, holmium:YAG laser
resection of the prostate (HoLRP) cost 24.5% less ($651) than
TURP [31]. These lower costs have been accredited to the
outpatient nature of laser treatment, shorter stays for
inpatients, reduced catheterisation time, and lower
complication rates. These anticipated benefits of the
ThuVARP procedure were not observed in the UNBLOCS
trial.
One of the major strengths of the present study was the
combination of the use of routine hospital PLICS data for
follow-up outpatient visits (including procedures) and
inpatient stays, reducing ascertainment bias. This method of
data collection also probably led to more complete data for
the NHS secondary care analysis and was less burdensome on
the research nurses than if a medical notes review had been
conducted. Additionally, detailed data collection during
surgery by research nurses meant the cost differences between
the two operations could accurately be established.
The successful blinding of the patients also meant that their
answers to the EQ-5D-5L would not be affected by the
knowledge of their treatment allocation.
There may have been an underestimate of uncertainty around
theatre costs from the use of simple imputation methods.
There were 10 more missing recovery times in the TURP
arm, which could have led to a slight overestimate of the
TURP costs, although this would not have affected the overall
conclusions. Equipment was costed using a list of bipolar
TURP equipment, as this was the most common procedure.
Even in the hypothetical scenario that monopolar fixed
equipment cost per procedure was double that of the bipolar
equipment (£15.64) it would not have had a significant effect
on the results.
Some uncertainty surrounds the wider NHS analysis. Prior to
the creation of the multiple imputed dataset the percentage of
cases that had complete NHS resource use was low and
differential between arms (43% ThuVARP: TURP 50%). This
potentially means that the data may not have been missing at
random (MAR), as possibly healthier men were completing
the questionnaires, and those in the ThuVARP arm did have
a slightly lower quality of life in terms of QALYS. The poor
completion of the 3- and 6-month resource use
questionnaires, also meant that it was not appropriate to
conduct the originally planned analyses from a patient and
societal perspective.
The present study has found that, from an NHS secondary
care perspective, TURP is the most likely cost-effective option
compared with ThuVARP, and there was little uncertainty
around this result. This trial provides valuable findings on the
short-term cost-effectiveness of TURP compared to
ThuVARP and modelling could extrapolate these results over
longer time horizons.
The expected reduction in costs of ThuVARP resulting from
its ability to be done as a daycase did not materialise and this
analysis confirms that TURP remains a cost-effective
procedure for men with BPO.
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